3 completed, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow lisavanbulin: new trials by email Literature Review of lisavanbulin trials Research Report on lisavanbulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Microtubule-Targeted Agent BAL101553, Radiation Therapy - Glioblastoma, MGMT-Unmethylated Glioblastoma | Phase 1 | Terminated | Basilea Pharmaceutica | 26 | 2017-12-15 | 2024-06-24 |
| Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma BAL101553, BAL101553 at MTD - Neoplasms | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 43 | 2016-08-24 | 2023-05-10 |
| Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion - Neoplasms | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 72 | 2015-05-20 | 2024-06-26 |
| An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors BAL101553 - Solid Organ Tumors | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 73 | 2011-06-01 | 2023-05-10 |
Glioblastoma (2) · Neoplasms (2) · Brain Neoplasms (1) · Glioma (1)
Switzerland (2) · United Kingdom (2) · Belgium (1) · Germany (1) · United States (1)
Thomas Kaindl, MD (2) · Marc Engelhardt, MD (1) · Matthias Holdhoff, MD (1)